PepGen Inc., (PEPG): Price and Financial Metrics
GET POWR RATINGS... FREE!
PEPG Stock Price Chart Interactive Chart >
PEPG Price/Volume Stats
|Current price||$16.96||52-week high||$17.81|
|Prev. close||$15.38||52-week low||$4.32|
|Day high||$17.19||Avg. volume||56,154|
|50-day MA||$15.00||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||400.80M|
PepGen Inc., (PEPG) Company Bio
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Most Popular Stories View All
PEPG Latest News Stream
|Loading, please wait...|
PEPG Latest Social Stream
View Full PEPG Social Stream
Latest PEPG News From Around the Web
Below are the latest news stories about PEPGEN INC that investors may wish to consider to help them evaluate PEPG as an investment opportunity.
PepGen, Inc. (PEPG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
PepGen, Inc. (PEPG) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
There remains an unmet need for medical advancement in the treatment Duchenne Muscular Dystrophy. Read about the opportunity for investors here.
HC Wainwright initiated coverage of PepGen Inc (NASDAQ: PEPG ) with a Buy rating and $26 price target . PepGen is developing next-generation antisense oligonucleotide (ASO) therapeutics for neuromuscular and neurologic diseases. PepGen''s lead candidate is PGN-EDO51, a peptide-conjugated ASO targeting Exon 51, which has shown significant exon-skipping activity and dystrophin expression in cardiac … Full story available on Benzinga.com
PEPG Price Returns